04.17.17
Dr. Yisheng Lee was appointed chief medical officer at Foresee Pharmaceuticals Co. and Dr. David Lau was named senior vice president, NCE Preclinical and Clinical Development.
Dr. Yisheng Lee will play a leading role in establishing strategies related to portfolio management, clinical trials, regulatory affairs, pharmacovigilance and risk management. He has broad experience in clinical practice, medical education, and academic research, and will network with academic institutions and clinical trial sites.
Dr. Lau will lead Foresee's NCE preclinical and clinical development, including pharmacokinetics, drug metabolism, bioanalysis, toxicology, and preclinical/clinical pharmacology. Dr. Lau will also play a strategic role in the scientific support related to the out-licensing/partnering of Foresee's programs and in the evaluation and selection of any new drug in-licensing opportunities.
Dr. Lee brings extensive leadership experience in patient care, new drug clinical trial execution and medical research. Dr. Lee has practiced pediatric hematology/oncology and held multiple academic appointments at Harvard, Duke, Stanford, and UCSF Medical Schools over the past 30 years.
Dr. Lau has successfully led NCE preclinical and clinical development in multiple pharmaceutical companies over the past 25 years. Most recently he was vice president, Preclinical Safety Assessment, leading activities in drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology, at Rigel Pharmaceuticals. Previously, Dr. Lau was senior director and West Coast Site Head in the Global Preclinical Development Department of Johnson & Johnson, and served as director of Pharmacokinetics and Drug Metabolism at Amgen.
Dr. Ben Chien, chairman and chief executive officer of Foresee said, "We are excited to have Drs. Lee and Lau join our leadership team, as they bring extensive drug development expertise that aligns perfectly with our portfolio and will greatly complement Foresee's global team. Dr. Lee has been a key contributor to Foresee's strategy as a non-executive Board member since the company's inception. We are excited to have him take on a more active operational role as part of our executive team. Dr. Lau's hands-on drug development experience covering the entire development life cycle will be invaluable as Foresee is planning to expedite and expand the development of its multiple NCE programs."
Dr. Yisheng Lee will play a leading role in establishing strategies related to portfolio management, clinical trials, regulatory affairs, pharmacovigilance and risk management. He has broad experience in clinical practice, medical education, and academic research, and will network with academic institutions and clinical trial sites.
Dr. Lau will lead Foresee's NCE preclinical and clinical development, including pharmacokinetics, drug metabolism, bioanalysis, toxicology, and preclinical/clinical pharmacology. Dr. Lau will also play a strategic role in the scientific support related to the out-licensing/partnering of Foresee's programs and in the evaluation and selection of any new drug in-licensing opportunities.
Dr. Lee brings extensive leadership experience in patient care, new drug clinical trial execution and medical research. Dr. Lee has practiced pediatric hematology/oncology and held multiple academic appointments at Harvard, Duke, Stanford, and UCSF Medical Schools over the past 30 years.
Dr. Lau has successfully led NCE preclinical and clinical development in multiple pharmaceutical companies over the past 25 years. Most recently he was vice president, Preclinical Safety Assessment, leading activities in drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology, at Rigel Pharmaceuticals. Previously, Dr. Lau was senior director and West Coast Site Head in the Global Preclinical Development Department of Johnson & Johnson, and served as director of Pharmacokinetics and Drug Metabolism at Amgen.
Dr. Ben Chien, chairman and chief executive officer of Foresee said, "We are excited to have Drs. Lee and Lau join our leadership team, as they bring extensive drug development expertise that aligns perfectly with our portfolio and will greatly complement Foresee's global team. Dr. Lee has been a key contributor to Foresee's strategy as a non-executive Board member since the company's inception. We are excited to have him take on a more active operational role as part of our executive team. Dr. Lau's hands-on drug development experience covering the entire development life cycle will be invaluable as Foresee is planning to expedite and expand the development of its multiple NCE programs."
